CTS 3497
Alternative Names: CTS-3497Latest Information Update: 04 Aug 2026
At a glance
- Originator CytosinLab Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action PRMT5 protein inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Lymphoma; Solid tumours
Most Recent Events
- 29 May 2026 Efficacy, pharmacokinetics, pharmacodynamic and adverse events data from a phase I/II trial in Solid tumours presented at 62nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2026)
- 22 Apr 2026 Pharmacodynamics data from preclinical studies in Solid tumours presented at the 117th Annual Meeting of the American Association for Cancer Research (AACR-2026) .
- 17 Oct 2025 Efficacy, pharmacokinetics and adverse events data from a phase I/II trial in Solid tumours and Lymphoma at the 50th European Society for Medical Oncology Congress (ESMO-2025)